Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005

Adolfsson, Jan; Garmo, Hans; Varenhorst, Eberhard; Ahlgren, Göran; Ahlstrand, Christer; Andrén, Ove; Bill‐Axelson, Anna; Bratt, Ola; Damber, Jan‐Erik; Hellström, Karin; Hellström, Magnus; Holmberg, Erik; Holmberg, Lars; Hugosson, Jonas; Johansson, Jan‐Erik; B, Petterson; Törnblom, Magnus; Widmark, Anders; Stattin, Pär

doi:10.1080/00365590701673625

Cited by 100 publications

(94 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prostate-specific antigen testing may be considered to introduce bias, as this screening technique may only detect certain types of tumour. There is no official recommendation in Sweden on PSA testing as part of health checkups or for screening purposes in men without lower urinary tract symptoms (Adolfsson et al, 2007), hence any bias that may be introduced by PSA is of limited relevance in our data.…”

Section: Discussionmentioning

confidence: 64%

“…These features of the study substantially reduce the potential risk of recall and selection biases, and, importantly, increase the generalisability of the study findings. According to the National Prostate Cancer Register data, the most common cause of diagnosis in Sweden was clinical symptom (about 80% in our data), followed by health checkup (Adolfsson et al, 2007). Prostate-specific antigen testing may be considered to introduce bias, as this screening technique may only detect certain types of tumour.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A prospective study of lifetime physical activity and prostate cancer incidence and mortality

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: The possible benefit of lifetime physical activity (PA) in reducing prostate cancer incidence and mortality is unclear. METHODS: A prospective cohort of 45 887 men aged 45 -79 years was followed up from January 1998 to December 2007 for prostate cancer incidence (n ¼ 2735) and to December 2006 for its subtypes and for fatal (n ¼ 190) prostate cancer. RESULTS: We observed an inverse association between lifetime (average of age 30 and 50 years, and baseline age) total PA levels and prostate cancer risk. Multivariate-adjusted incidence in the top quartile of lifetime total PA decreased by 16% (95% confidence interval (CI) ¼ 2 -27%) compared with that in the bottom quartile. We also observed an inverse association between average lifetime work or occupational activity and walking or bicycling duration and prostate cancer risk. Compared with men who mostly sit during their main work or occupation, men who sit half of the time experienced a 20% lower risk (95% CI ¼ 7 -31%). The rate ratio linearly decreased by 7% (95% CI ¼ 1 -12%) for total, 8% (95% CI ¼ 0 -16%) for localised and 12% (95% CI ¼ 2 -20%) for advanced prostate cancer for every 30 min per day increment of lifetime walking or bicycling in the range of 30 to 120 min per day. CONCLUSION: Our results suggest that not sitting for most of the time during work or occupational activity and walking or bicycling more than 30 min per day during adult life is associated with reduced incidence of prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 64%

Section: Discussionmentioning

confidence: 99%

A prospective study of lifetime physical activity and prostate cancer incidence and mortality

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The other three populations were from our collaborative research group, including a hospital-based case series from the JHH, and two populationbased studies based on the National Prostate Cancer Register of Sweden; a case-control study; CAncer Prostate in Sweden (CAPS) (41,26), and a case series of PCa patients treated for localized PCa (PROCAP) (42,43).…”

Section: Methodsmentioning

confidence: 99%

Inherited genetic variant predisposes to aggressive but not indolent prostate cancer

Zheng

Isaacs

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

View full text Add to dashboard Cite

Autopsy studies suggest that most aging men will develop lesions that, if detected clinically, would be diagnosed as prostate cancer (PCa). Most of these cancers are indolent and remain localized; however, a subset of PCa is aggressive and accounts for more than 27,000 deaths in the United States annually. Identification of factors specifically associated with risk for more aggressive PCa is urgently needed to reduce overdiagnosis and overtreatment of this common disease. To search for such factors, we compared the frequencies of SNPs among PCa patients who were defined as having either more aggressive or less aggressive disease in four populations examined in the Genetic Markers of Susceptibility (CGEMS) study performed by the National Cancer Institute. SNPs showing possible associations with disease severity were further evaluated in an additional three independent study populations from the United States and Sweden. In total, we studied 4,829 and 12,205 patients with more and less aggressive disease, respectively. We found that the frequency of the TT genotype of SNP rs4054823 at 17p12 was consistently higher among patients with more aggressive compared with less aggressive disease in each of the seven populations studied, with an overall P value of 2.1 × 10−8 under a recessive model, exceeding the conservative genome-wide significance level. The difference in frequency was largest between patients with high-grade, non–organ-confined disease compared with those with low-grade, organ-confined disease. This study demonstrates that inherited variants predisposing to aggressive but not indolent PCa exist in the genome, and suggests that the clinical potential of such variants as potential early markers for risk of aggressive PCa should be evaluated.

show abstract

“…[14][15][16][17] In brief, the NPCR contains data on tumour characteristics according to the tumour, node status, metastasis TNM classification, 18 histological grade, date of diagnosis, serum levels of prostatespecific antigen (PSA) at the time of diagnosis, and primary treatment delivered or decided within 6 months after diagnosis for 98% of all men with prostate cancer in Sweden since 1998. In this study NPCR was linked to Cause of Death Register, the Prescribed Drug Register, the National Hospital Discharge Register and the Day Surgery Register.…”

mentioning

confidence: 99%

Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden

Robinson

Garmo

Lindahl

et al. 2011

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

In observational studies of men with prostate cancer, men on endocrine treatment (ET) have had an increased risk of ischemic heart disease (IHD) and stroke. However, prostate cancer per se may increase risk of IHD and stroke and men on ET may have been at increased risk already prior to initiation of ET. We assessed the incidence of IHD and stroke in men with prostate cancer before and during different endocrine treatments. The hazard ratio (HR) of IHD and stroke in 39,051 men with prostate cancer vs. a matched control population without prostate cancer was assessed by use of Cox proportion hazard models. An increased risk was found among 30,883 men with prostate cancer who did not receive ET, with a HR of 1.08 (95% CI 1.00-1.18) for IHD and 1.10 (95%CI 1.00-1.21) for stroke. In 8,168 men who initiated ET during the observation period, the risk of IHD was significantly higher (p 5 0.014), during ET (HR 1.40, 95% CI 1.17-1.67) compared with before initiation of ET (HR of 0.98, 95% CI 0.72-1.33), whereas no such increase was found for stroke. Regardless of treatment, men with prostate cancer had a small increase in risk of IHD and stroke and initiation of ET was associated with a further increase in risk of IHD. Our data underline the importance of a proper indication for ET because many men with low-risk prostate cancer currently receive ET.

show abstract

Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005

Cited by 100 publications

References 35 publications

A prospective study of lifetime physical activity and prostate cancer incidence and mortality

A prospective study of lifetime physical activity and prostate cancer incidence and mortality

Inherited genetic variant predisposes to aggressive but not indolent prostate cancer

Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden

Contact Info

Product

Resources

About